Conference in Boston, October 19 - 20, 2006 - - - Presentation will include
an update on critical care glucose monitor development and clinical studies
FRANKLIN, Mass., Oct. 18 /PRNewswire-FirstCall/ -- Sontra Medical
Corporation (Nasdaq: SONT) announced today that the Company will be
presenting its technology and critical care glucose monitoring developments
at the In3 East Conference on October 19 - 20, 2006 at the Westin Hotel
Copley Place in Boston, MA.
Thomas Davison, Ph.D. President and CEO of Sontra will be presenting
the Company's business highlights including findings from clinical studies
of its Symphony(TM) Continuous Transdermal Glucose Monitor ("CTGM") on
subjects with diabetes and studies that are underway at the Tufts/New
England Medical Center. The Symphony CTGM is being developed to help
anesthesiologists and critical care nurses manage intensive insulin therapy
which has been proven to be necessary to reduce mortality and complications
significantly in cardiac and other surgical patients.
"Our development goals for the Symphony CTGM are to provide a critical
care monitor that provides continuous non-invasive glucose readings for
critically ill patients," stated Dr. Davison. "Clinical studies on
volunteers with diabetes completed this summer demonstrated Symphony's
reliability and accuracy to monitor glucose activity in a hospital critical
care setting."
The Company's first glucose monitoring clinical study is being
conducted at the Tufts/New England Medical Center in Boston on patients
undergoing heart surgery. The Symphony CTGM sensor is being applied to
patients prior to surgery so that glucose monitoring can be evaluated
throughout surgery and continued until the patient is released from the
cardiac critical or intensive care unit. Dr. Davison commented, "We have
shown that the Symphony CTGM can monitor glucose levels for 24 hours
through cardiac surgery and recovery in the cardiac care unit. The system
was able to compensate for low body temperature during extracorporeal
perfusion and after the operation there was no apparent interference from
edema and medications."
About Sontra Medical Corporation (http://www.sontra.com)
Sontra Medical Corporation is a technology leader in transdermal
science and is developing a non-invasive, continuous transdermal glucose
monitor ("CTGM") for principal use in the Intensive Care Market. Through
its platform technology, the SonoPrep(R) Permeation System, combined with
technical competencies in transdermal drug formulation, analysis, delivery
systems and biosensors, the Company is creating a new paradigm in
transdermal drug delivery and diagnosis. The CTGM and other company
products are being developed for several billion dollar market
opportunities, all utilizing skin permeation, chemistry and biosensor
technology developed by the Company. In addition, the Company is developing
products for transdermal delivery of large molecule drugs and vaccines.
Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements as that term is
defined in the Private Securities Litigation Reform Act of 1995. Any
forward- looking statements contained herein are based on current
expectations, but are subject to a number of risks and uncertainties. The
factors that could cause actual future results to differ materially from
current expectations include, but are not limited to, risks and
uncertainties relating to the Company's ability to develop, market and sell
products based on its technology, including a continuous transdermal
glucose monitor for the hospital ICU market; the expected size of the
market for the continuous transdermal glucose monitor for the hospital ICU
market; the expected benefits and efficacy of the SonoPrep device in
connection with diagnostics, vaccine delivery, glucose monitoring and
transdermal science; the availability of substantial additional funding to
conduct research and development, clinical studies and future product
commercialization; and, the Company's business, research, product
development, regulatory approval, marketing and distribution plans and
strategies. These and other factors are identified and described in more
detail in our filings with the SEC, including, without limitation, our
respective annual reports on Form 10-KSB for the year ended December 31,
2005, our most recent quarterly reports on Form 10-QSB, and our current
reports on Form 8-K. We do not undertake to update these forward-looking
statements made by us.
SonoPrep is a registered trademark of Sontra Medical Corporation. All
other company, product or service names mentioned herein are the trademarks
or registered trademarks of their respective owners.
Investor Relations Contact:
Harry G. Mitchell, CFO
508-530-0311
hmitchell@sontra.com
SOURCE Sontra Medical Corporation
back to top
